Trials / Recruiting
RecruitingNCT05263570
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
The Efficiency for Patient With Stage II-III HR+/HER2+ Early Breast Cancer With Standard Neoadjuvant Therapy: a Retrospective, Multicenter Study in Real World Settings.
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- Shengjing Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
Detailed description
This study collected patients used standard neoadjuvant therapy (TCbHP/THP/EC-THP/AC-THP) among stage II-III HR+/HER2+ early breast cancer, and to describe patient clinical characteristics and clinical outcomes of them in real world settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Standard Therapy | Standard Therapy, including TCbHP, THP, EC-THP, AC-THP |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-12-31
- Completion
- 2026-12-31
- First posted
- 2022-03-02
- Last updated
- 2022-09-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05263570. Inclusion in this directory is not an endorsement.